Isopentyl caffeate as a promising drug for the treatment of leishmaniasis : An in silico and in vivo study

Mota, Wanessa S.Oliveira, Simone S.C.Pereira, Matheus M.Souza, Damião P.Castro, MayaraGomes, Pollyanna S.Guedes, Herbert L.M.Souza, Vinícius F.Santos, André L.S.Albuquerque-Junior, Ricardo L.C.Cardoso, Juliana C.Blanco-Llamero, CristinaJain, SonaSouto, Eliana B.Severino, Patrícia2026-02-052026-02-052024-01Mota, W S, Oliveira, S S C, Pereira, M M, Souza, D P, Castro, M, Gomes, P S, Guedes, H L M, Souza, V F, Santos, A L S, Albuquerque-Junior, R L C, Cardoso, J C, Blanco-Llamero, C, Jain, S, Souto, E B & Severino, P 2024, 'Isopentyl caffeate as a promising drug for the treatment of leishmaniasis : An in silico and in vivo study', Current Research in Biotechnology, vol. 7, 100209. https://doi.org/10.1016/j.crbiot.2024.1002092590-2628https://hdl.handle.net/10641/7839Publisher Copyright: © 2024 The Author(s)6857628enghttp://creativecommons.org/licenses/by-nc-nd/4.0/ADMEBioavailabilityIn silicoIsopentyl caffeateLeishmaniaPharmacokineticsBiotechnologySDG 3 - Good Health and Well-beingYesyesIsopentyl caffeate as a promising drug for the treatment of leishmaniasis : An in silico and in vivo studyjournal articleopen access10.1016/j.crbiot.2024.100209https://www.scopus.com/pages/publications/85189820569https://www.scopus.com/pages/publications/85189820569#tab=citedBy